Details

Autor(en) / Beteiligte

• LE GOUILL, Steven
• DE GUIBERT, Sophie
• FRUCHART, Christophe
• DECONINCK, Eric
• FITOUSSI, Olivier
• GASTAUD, Lauris
• DELWAIL, Vincent
• GABARRE, Jean
• GRESSIN, Rémy
• BLANC, Michel
• FOUSSARD, Charles
• SALLES, Gilles
• PLANCHE, Lucie
• BRICE, Pauline
• DUPUIS, Jehan
• CARTRON, Guillaume
• VAN HOOF, Achiel
• CASASNOVAS, Olivier
• GYAN, Emmanuel
• TILLY, Hervé

Titel

Impact of the use of autologous stem cell transplantation at first relapse both in naïve and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study

Ist Teil von

• Haematologica (Roma), 2011-08, Vol.96 (8), p.1128-1135

Ort / Verlag

Pavia: Ferrata Storti Foundation

Erscheinungsjahr

2011

Quelle

MEDLINE

Beschreibungen/Notizen

• We analyzed detailed characteristics and salvage treatment in 175 follicular lymphoma patients from the FL2000 study who were in progression after first-line therapy with or without addition of rituximab to chemotherapy and interferon. The impact of using autologous stem cell transplantation and/or rituximab administration at first progression was investigated, taking into account initial therapy. With a median follow up of 31 months, 3-year event free and overall survival rates after progression were 50% (95%CI 42-58%) and 72% (95%CI 64-78%), respectively. The 3-year event free rate of rituximab re-treated patients (n=112) was 52% (95%CI 41-62%) versus 40% (95%CI 24-55%) for those not receiving rituximab second line (n=53) (P=0.075). There was a significant difference in 3-year overall survival between patients receiving autologous stem cell transplantation and those not: 92% (95%CI 78-97%) versus 63% (95%CI 51-72%) (P=0.0003), respectively. In multivariate analysis, both autologous stem cell transplantation and period of progression/relapse affected event free and overall survival. Regardless of front-line rituximab exposure, this study supports incorporating autologous stem cell transplantation in the therapeutic approach at first relapse for follicular lymphoma patients.